Table 2 Cetuximab for advanced colorectal cancer
Author, year | Pat. [n] | Treatment regimen | Median PFS [months] | Median OS [months] | ||
|---|---|---|---|---|---|---|
| Â | Â | Â | + cet | - cet | + cet | - cet |
Tabernero, 2007 [29] | 43 | FOLFOX/cetuximab | 12.3 | - | 30.5 | - |
Borner, 2008 [30] | 74 | CAPOX/cetuximab | 7.2 | 5.8 | 20.5 | 16.5 |
Arnold, 2008 [31] | 49 | FUFOX/cetuximab | 8.1 | - | 28.2 | - |
Cartwright, 2008 [32] | 70 | CAPIRI/cetuximab | 8.1 | - | 20.5 | - |
Van Cutsem, 2009 [33] | 348* | FOLFIRI/cetuximab | 9.9* | 8.7* | 24.9* | 21* |
Bokemeyer, 2009 [34] | 134* | FOLFOX/cetuximab | 7.7* | 7.2* | - | - |
Tol, 2009 [35] | 755 | CAPOX/bev/cet | 9.4 | 10.7 | 19.4 | 20.3 |
Maughan, 2011 [36] | 729* | FOLFOX/CAPOX/cet | 8.6* | 8.6* | 17.0* | 17.9* |
Tveit, 2012 [37] | 566 | FLOX/cetuximab | 8.3 | 7.9 | 19.7 | 20.4 |